ArticleClinical pharmacology and therapeutics2007
New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.
Article in Clinical pharmacology and therapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Enhancement of mucosal innate and adaptive immunity following intranasal immunization of mice with a bovine adenoviral vector.Frontiers in immunology · 2023Article
- A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice.Cell reports. Medicine · 2021Article
- Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.Clinical & translational immunology · 2021Review
- Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.Vaccines · 2020Review
- Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.Vaccine · 2018Article
- A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose.Molecular therapy. Methods & clinical development · 2018Article
- Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.PloS one · 2017Article
- Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus.Scientific reports · 2016Article
- Adenovirus-based vaccines against avian-origin H5N1 influenza viruses.Microbes and infection · 2015Review
- Progress on adenovirus-vectored universal influenza vaccines.Human vaccines & immunotherapeutics · 2015Review
- Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.Virus research · 2013Article
- H5N1 vaccines in humans.Virus research · 2013Review
- Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice.Virus research · 2013Article
- Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.Future virology · 2013Article
- Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.PloS one · 2013Article
- Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.Viruses · 2012Review
- Novel viral vectored vaccines for the prevention of influenza.Molecular medicine (Cambridge, Mass.) · 2012Review
- Article
- Development of adenoviral vector-based mucosal vaccine against influenza.Journal of molecular medicine (Berlin, Germany) · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Highly pathogenic avian H5N1 influenza viruses that are currently circulating in southeast Asia may acquire the potential to cause the next influenza pandemic. A number of alternate approaches are being pursued to generate cross-protective, dose-sparing, safe, and effective vaccines, as traditional vaccine approaches, i.e., embryonated egg-grown, are not immunogenic. We developed a replication-incompetent adenoviral vector-based, adjuvant- and egg-independent pandemic influenza vaccine strategy as a potential alternative to conventional egg-derived vaccines. In this paper, we address suboptimal dose and longevity of vaccine-induced protective immunity and demonstrate that a vaccine dose as little as 1 x 10(6) plaque-forming unit (PFU) is sufficient to induce protective immune responses against a highly pathogenic H5N1 virus. Furthermore, the vaccine-induced humoral and cellular immune responses and protective immunity persisted at least for a year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.